Kimia Biosciences Ltd. engages in the manufacture and distribution of pharmaceutical products. The company is headquartered in New Delhi, Delhi. The company went IPO on 2016-03-21. The firm provides its products under various categories: active pharmaceutical ingredients (APIs), intermediates and formulations. The firm's commercial products include acotiamide hydrochloride hydrate, azelnidipine, benfotiamine, benidipine hydrochloride, citicoline sodium, gliclazide, levosulpiride, luliconazole, oxaceprol, prucalopride succinate, teneligliptin hydrobromide hydrate, vildagliptin, fimasartantrihydrate potassium, obeticholic acid and ursodeoxycholic acid.
Loading chart…
This company hasn't held an earnings call in the last six months, so there's no recent commentary from management. Our deep dives are built on what management actually said, so we haven't prepared one.